The accumulated experience with the use of mycophenolate mofetil in primary glomerulonephritis (Q34618530)

3 August 2017

1 reference

title

The accumulated experience with the use of mycophenolate mofetil in primary glomerulonephritis (English)

1 reference

3 August 2017

1 reference

Maria Koukoulaki

1

1 reference

3 August 2017

Dimitrios S Goumenos

series ordinal

2

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 May 2010

1 reference

Expert Opinion on Investigational Drugs

3 August 2017

published in

1 reference

3 August 2017

volume

19

1 reference

3 August 2017

issue

5

1 reference

3 August 2017

page(s)

673-687

1 reference

Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543781003765461

Immunosuppressive medications for renal transplantation: a multiple choice question

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003765461

Mycophenolate mofetil and its mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003765461

Mycophenolate mofetil slows progression in anti-thy1-induced chronic renal fibrosis but is not additive to a high dose of enalapril

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003765461

Mycophenolate mofetil prevents the development of glomerular injury in experimental diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003765461

Prevention of early renal injury by mycophenolate mofetil and its mechanism in experimental diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003765461

Nephrin and podocin loss is prevented by mycophenolate mofetil in early experimental diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003765461

Molecular basis of the glomerular filtration: nephrin and the emerging protein complex at the podocyte slit diaphragm

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003765461

Glomerular abundance of nephrin and podocin in experimental nephrotic syndrome: different effects of antiproteinuric therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003765461

Mycophenolic acid antagonizes the activation of cultured human mesangial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003765461

A meta-analysis of cytotoxic treatment for frequently relapsing nephrotic syndrome in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003765461

Mycophenolate mofetil in the treatment of resistant idiopathic nephrotic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003765461

Frequently relapsing nephrotic syndrome: treatment with mycophenolate mofetil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003765461

Mycophenolate mofetil in steroid/cyclosporine-dependent/resistant nephrotic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003765461

Mycophenolate mofetil treatment for primary glomerular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003765461

Mycophenolate therapy in frequently relapsing minimal change disease that has failed cyclophosphamide therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003765461

Adult minimal-change disease: clinical characteristics, treatment, and outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003765461

Mycophenolate mofetil versus cyclosporine for remission maintenance in nephrotic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003765461

Focal segmental glomerulosclerosis in nephrotic adults: presentation, prognosis, and response to therapy of the histologic variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003765461

A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003765461

Cyclosporine in the treatment of idiopathic focal segmental glomerulosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003765461

Novel therapy of focal glomerulosclerosis with mycophenolate and angiotensin blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003765461

Mycophenolate mofetil or standard therapy for membranous nephropathy and focal segmental glomerulosclerosis: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003765461

Idiopathic membranous nephropathy: diagnosis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003765461

Use of mycophenolate mofetil in resistant membranous nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003765461

Mycophenolate mofetil in treatment of idiopathic stages III-IV membranous nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003765461

Mycophenolate mofetil in idiopathic membranous nephropathy: a clinical trial with comparison to a historic control group treated with cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003765461

Mycophenolate mofetil monotherapy in membranous nephropathy: a 1-year randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003765461

Prospective controlled study on mycophenolate mofetil and prednisolone in the treatment of membranous nephropathy with nephrotic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003765461

Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003765461

Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003765461

Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003765461

Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003765461

Mycophenolate mofetil treatment for IgA nephropathy: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003765461

Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003765461

Novel anti-Pneumocystis carinii effects of the immunosuppressant mycophenolate mofetil in contrast to provocative effects of tacrolimus, sirolimus, and dexamethasone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003765461

The impact of novel immunosuppressive agents on infections in organ transplant recipients and the interactions of these agents with antimicrobials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003765461

Delayed severe pneumonia in mycophenolate mofetil-treated patients with IgA nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003765461

Mycophenolate mofetil and risk of developing malignancy after orthotopic heart transplantation: analysis of the transplant registry of the International Society for Heart and Lung Transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003765461

Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003765461

A Randomized, Controlled Trial of Steroids and Cyclophosphamide in Adults with Nephrotic Syndrome Caused by Idiopathic Membranous Nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003765461

A BLINDED, LONG-TERM, RANDOMIZED MULTICENTER STUDY OF MYCOPHENOLATE MOFETIL IN CADAVERIC RENAL TRANSPLANTATION

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003765461

10.1517/13543781003765461

21 January 2018

Identifiers

DOI

1 reference

release_c432cjenvzdpbfqt72suwv3dna

3 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/c432cjenvzdpbfqt72suwv3dna

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference